AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,830,996 | +702.9% | 36,200 | +641.2% | 0.00% | – |
Q2 2023 | $228,034 | +7335.1% | 4,884 | -93.9% | 0.00% | -100.0% |
Q1 2023 | $3,067 | -77.3% | 80,166 | -67.5% | 0.00% | -71.4% |
Q4 2022 | $13,537 | -99.7% | 247,017 | -52.6% | 0.01% | +133.3% |
Q2 2022 | $4,921,000 | +431.4% | 520,769 | +698.2% | 0.00% | – |
Q1 2022 | $926,000 | +121.5% | 65,244 | +230.5% | 0.00% | – |
Q4 2021 | $418,000 | -86.7% | 19,743 | -81.7% | 0.00% | -100.0% |
Q1 2021 | $3,133,000 | -54.1% | 107,992 | -59.2% | 0.00% | -60.0% |
Q4 2020 | $6,822,000 | +41.7% | 264,411 | +69.2% | 0.01% | -16.7% |
Q3 2020 | $4,813,000 | +49.1% | 156,314 | +20.6% | 0.01% | +50.0% |
Q2 2020 | $3,229,000 | +136.0% | 129,565 | +100.8% | 0.00% | +33.3% |
Q1 2020 | $1,368,000 | -18.3% | 64,539 | -12.3% | 0.00% | 0.0% |
Q3 2019 | $1,674,000 | -47.9% | 73,621 | -56.1% | 0.00% | -40.0% |
Q2 2019 | $3,212,000 | – | 167,746 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |